Related Experiment Video
Updated: Jul 5, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
The Janus of lupus--benefits and risks with B-cell therapy
1Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden. ronald.van.vollenhoven@ki.se
Abstract:
Janus was the Roman god of doorways and beginnings. Thus, if B-cell directed therapy is indeed the beginning of a new era in SLE therapy, his would be an appropriate face to regard in this context. But there is a problem: he is a two-faced god. Janus faces in two different directions: past and future, youth and adulthood, barbarism and civility. With respect to biological treatments, perhaps Janus' faces are the efficacy and the safety dimensions of therapy. In this review, I will consider Janus' second face, the safety side of B-cell therapy. I will argue that, while safety data have been rather reassuring so far, vigilance is required; and I will point out three specific mistaken assumptions regarding the safety of B-cell directed therapy in SLE.
Related Concept Videos
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Mesenchymal Stem Cells
Treatment Resistent Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The JAK-STAT Signaling Pathway
